{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:49:00Z","timestamp":1772160540768,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,7]],"date-time":"2008-04-07T00:00:00Z","timestamp":1207526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\/Aim:<\/jats:bold>\n                    Liver biopsy has so far been the only method to accurately follow the progression of primary biliary cirrhosis (PBC). The stage and the severity of lymphocytic piecemeal necrosis (LPN) have been shown to be an independent factor for the development of cirrhosis. In this 3\u2010year prospective study, we evaluated the diagnostic value of several liver function tests, surrogate markers of fibrogenesis, hyaluronic acid (HA), procollagen III N\u2010terminal peptide (S\u2010PIIINP), cholestanol and plant sterols in noncirrhotic PBC patients treated with ursodeoxycholic acid (UDCA) or with UDCA and budesonide to assess the stage, inflammation and fibrosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Seventy\u2010seven stage I\u2013III PBC patients were included into the study, with control biopsy at 36 months. Serum liver enzymes, bile acids (BA), HA, PIIINP, immunoglobulins, lipids and cholesterol precursors and plant sterols were measured at baseline and at 36 months.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Aspartate aminotransferase (AST), HA, BA and PIINP were significantly different between stages I to III and differentiated mild (F0F1) from moderate (F2F3) fibrosis. The combination of these variables (PBC score) exhibited best sensitivity and specificity, compared with AST\/platelet ratio, Forns' score and fibrosis index. Using a cut\u2010off value of 66 for the PBC score, the sensitivity was 81.4% and specificity was 65.2% for classifying the stage of PBC, regarding the stage the and fibrosis in noncirrhotic PBC.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Serum HA, BA, PIIINP and AST may serve as valuable simple tools to monitor the treatment response to UDCA in early stages of PBC. Combinations of these biomarkers into a single index further potentiate the diagnostic value of such measurements.\n                  <\/jats:p>","DOI":"10.1111\/j.1478-3231.2008.01722.x","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T09:15:23Z","timestamp":1282900523000},"page":"787-797","source":"Crossref","is-referenced-by-count":20,"title":["Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy"],"prefix":"10.1111","volume":"28","author":[{"given":"Martti","family":"F\u00e4rkkil\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henna","family":"Rautiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi","family":"K\u00e4rkk\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna\u2010L.","family":"Karvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heimo","family":"Nurmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onni","family":"Niemel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611213352107"},{"key":"e_1_2_7_3_2","first-page":"865","article-title":"Asymptomatic primary biliary cirrhosis","volume":"53","author":"Prince MI","year":"2004","journal-title":"clinical features, prognosis, and symptom progression in a large population based cohort"},{"key":"e_1_2_7_4_2","first-page":"57","article-title":"Primary biliary cirrhosis","volume":"24","author":"Nyberg A","year":"1989","journal-title":"clinical features and outcome, with special reference to asymptomatic disease"},{"key":"e_1_2_7_5_2","first-page":"707","article-title":"Primary biliary cirrhosis","volume":"20","author":"Mahl TC","year":"1994","journal-title":"survival of a large cohort of symptomatic and asymptomatic patients. Followed for 24 years"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90325-7"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301903"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90021-3"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220311"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290301"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20240"},{"key":"e_1_2_7_12_2","first-page":"561","article-title":"Long term effects of ursodeoxycholic acid in primary biliary cirrhosis","volume":"32","author":"Pares A","year":"2000","journal-title":"results of a double-blind controlled multicentric trial. UDCA Cooperative Group from Spanish association for the study of liver"},{"key":"e_1_2_7_13_2","first-page":"652","article-title":"Primary biliary cirrhosis","volume":"122","author":"Corpechot C","year":"2002","journal-title":"incidence and predictive factors of cirrhosis development in ursodiol treated patients"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00192-2"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-951598"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21046"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.12.013"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01304.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0918.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)90046-2"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.6.860"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/83799"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2004.00002.x"},{"key":"e_1_2_7_24_2","first-page":"747","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis","volume":"41","author":"Rautiainen H","year":"2005","journal-title":"a three-year randomized trial"},{"key":"e_1_2_7_25_2","first-page":"183","volume-title":"Bile Acid and Cholesterol in Health and Disease","author":"Miettinen TA","year":"1983"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(82)90393-X"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36128"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432479"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_7_31_2","first-page":"310","article-title":"Non\u2010invasive evaluation of fibrosis","volume":"55","author":"Pinzani M.","year":"2006","journal-title":"don't count your chickens before they're hatched"},{"key":"e_1_2_7_32_2","first-page":"1704","article-title":"Serum markers detect the presence of liver fibrosis","volume":"127","author":"Rosenberg WM","year":"2004","journal-title":"a cohort study"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2008.01722.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2008.01722.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T19:51:22Z","timestamp":1696189882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2008.01722.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1478-3231.2008.01722.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01722.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1116879.572846","asserted-by":"object"}]},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,4]]}}}